OBJECTIVES: Biomarkers that detect pancreatic cancer at earlier stages could improve the outcome of this deadly disease. METHODS: We investigated a dozen biomarker candidates for their potential as pancreatic cancer blood biomarkers using enzyme-linked immunosorbent assays. RESULTS: Among them, the macrophage migration inhibitory factor and osteopontin blood tests were nearly perfect in distinguishing pancreatic cancer cases from healthy controls (100% and 95% sensitivity, respectively, at 100% specificity). Five biomarker candidates were then tested on an expanded set of diseased controls, which included sera from patients with pancreatitis. The sensitivity dropped significantly for all 5 candidate markers. CONCLUSIONS: Our results suggest that biomarker candidates could fail in various steps of biomarker development. Earlier knowledge of candidate biomarker flaws could lead to strategies to overcome the flaw or alternatively lead to earlier termination of biomarkers that are prone to failure in the later phases of validation testing.
OBJECTIVES: Biomarkers that detect pancreatic cancer at earlier stages could improve the outcome of this deadly disease. METHODS: We investigated a dozen biomarker candidates for their potential as pancreatic cancer blood biomarkers using enzyme-linked immunosorbent assays. RESULTS: Among them, the macrophage migration inhibitory factor and osteopontin blood tests were nearly perfect in distinguishing pancreatic cancer cases from healthy controls (100% and 95% sensitivity, respectively, at 100% specificity). Five biomarker candidates were then tested on an expanded set of diseased controls, which included sera from patients with pancreatitis. The sensitivity dropped significantly for all 5 candidate markers. CONCLUSIONS: Our results suggest that biomarker candidates could fail in various steps of biomarker development. Earlier knowledge of candidate biomarker flaws could lead to strategies to overcome the flaw or alternatively lead to earlier termination of biomarkers that are prone to failure in the later phases of validation testing.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: A Kolb; J Kleeff; A Guweidhi; I Esposito; N A Giese; H Adwan; T Giese; M W Büchler; M R Berger; H Friess Journal: Cancer Biol Ther Date: 2005-07-05 Impact factor: 4.742
Authors: Sheng Pan; Ruedi Aebersold; Ru Chen; John Rush; David R Goodlett; Martin W McIntosh; Jing Zhang; Teresa A Brentnall Journal: J Proteome Res Date: 2009-02 Impact factor: 4.466
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: N Moniaux; S Chakraborty; M Yalniz; J Gonzalez; V K Shostrom; J Standop; S M Lele; M Ouellette; P M Pour; A R Sasson; R E Brand; M A Hollingsworth; M Jain; S K Batra Journal: Br J Cancer Date: 2008-04-08 Impact factor: 7.640
Authors: Sheng Pan; Ru Chen; Randall E Brand; Sarah Hawley; Yasuko Tamura; Philip R Gafken; Brian P Milless; David R Goodlett; John Rush; Teresa A Brentnall Journal: J Proteome Res Date: 2012-02-08 Impact factor: 4.466
Authors: Sheng Pan; Ru Chen; David A Crispin; Damon May; Tyler Stevens; Martin W McIntosh; Mary P Bronner; Argyrios Ziogas; Hoda Anton-Culver; Teresa A Brentnall Journal: J Proteome Res Date: 2011-03-28 Impact factor: 4.466
Authors: John B Kisiel; Tracy C Yab; William R Taylor; Suresh T Chari; Gloria M Petersen; Douglas W Mahoney; David A Ahlquist Journal: Cancer Date: 2011-09-22 Impact factor: 6.860
Authors: Katherine E Poruk; Matthew A Firpo; Courtney L Scaife; Douglas G Adler; Lyska L Emerson; Kenneth M Boucher; Sean J Mulvihill Journal: Pancreas Date: 2013-03 Impact factor: 3.327
Authors: Justin E Mirus; Yuzheng Zhang; Michael A Hollingsworth; Joell L Solan; Paul D Lampe; Sunil R Hingorani Journal: Mol Cell Proteomics Date: 2014-09-15 Impact factor: 5.911
Authors: Brian M Nolen; Randall E Brand; Denise Prosser; Liudmila Velikokhatnaya; Peter J Allen; Herbert J Zeh; William E Grizzle; Ying Huang; Aleksey Lomakin; Anna E Lokshin Journal: PLoS One Date: 2014-04-18 Impact factor: 3.240